CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSICUM	SPECIFIC	*Second*	6577	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OLEORESIN	TESTS/*Limit of Nonivamide*	*Supplement to USP36–NF31*					*Supplement to USP37–NF32*	*Acceptance criteria*: Change on the dried basis to: on the anhydrous basis
RISPERIDONE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP36–NF31*	6690	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a 98.9: 0.5: 0.30: 0.3 (area %) mixture of four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis* -3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyri do[1,2-*a*]pyrimidin-4-one]. 0.3% of *Bicyclorisperido* *ne*: 3-(4-Fluoro- 2-hydroxypheny l)-1-[2-(6,7,8,9-t etrahydro-2-met hyl-4 -oxo-4*H* -pyr ido-[1,2 -*a*]pyrimidin-3-yl)e thyl]-1-aza-2-az oniabicyclo[2.2. 2]oct-2-ene iodide. 0.3% of *Z*- *Oxime*: (*Z*)-3-[2-[4-(2,4-Dif luorophenyl) (hy droxyimino)met hyl]-1-piperidiny l]ethyl]-6,7,8,9-t etrahydro-2-met hyl-4*H* -pyri

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								do[1,2-*a*]pyrimidin-4-one . to: Contains a mixture of the following four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis* -3-[2-[4-(6-Fluor o-1,2-benzisoxa zol-3-yl)-1-piperi dinyl]ethyl]-6,7, 8,9-tetrahydro-2 -methy l-4*H* -pyri do[1,2-*a*]pyrimidin-4-one -*N*-oxide. 0.3% of *Bicyclorisperid one*: 3-(4-Fluoro -2-hydroxyphen yl)-1-[2-(6,7,8,9- tetrahydro-2-me

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								thyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z-Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl) (hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
BOSWELLIA SERRATA	COMPOSITION */Content of Keto-Derivatives of ?-Boswellic Acids/System suitability/Suitability requirements*	*USP36–NF31*	1366	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Tailing factor*: Change 11-keto-?-boswellic acid peak to: 3-acetyl-11-ket

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-?-boswellic acid peak
APROTININ	*Limit of des-Ala-aprotinin and des-Ala-des-Gly-aprotinin*	*USP36–NF31*	2522	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Change the subsection head *Capillary zone electrophoresis system* (see *Capillary Electrophoresis* under *Biotechnology-Derived Articles—Test* <1047>)— to: *Capillary zone electrophoresis system*—
KETOROLAC TROMETHAMINE TABLETS	IMPURITIES/*Organic Impurities*	*USP36–NF31*	4042	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Sample solution*: Change Proceed as directed for the *Sample stock solution* in the *Assay*. to: Proceed as directed for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RISPERIDONE	*USP Reference standards <11>*	*USP36–NF31*	5063	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	*Sample solution* in the *Assay*. Line 7 of USP Risperidone System Suitability Mixture RS: Change 9-Hydroxyrisperidone-(6*RS*)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2,6-dimethyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: 9-Hydroxyrisperidone: (9*RS*)-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-9-h

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
CHINESE SALVIA	COMPOSITION /*Content of Salvianolic Acid B*	*Second Supplement to USP36–NF31*	6331	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 16 of *Analysis*: Change *W* = weight of Chinese Salvia used to prepare the *Sample solution* (mg) to: *W* = weight of Chinese Salvia used to prepare the *Sample stock solution* (mg)
LORATADINE	IMPURITIES/*Organic Impurities, Procedure 1*	*Second Supplement to USP36–NF31*	6650	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of Note: Change 4,8-dichloro-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridin-11-one

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 4,8-dichloro-5,6-dihydro-11*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridin-11-one
POLYETHYLENE GLYCOL MONOMETHYL ETHER	IMPURITIES/*Limit of 2-Methoxyethanol*	*USP36–NF31*	2142	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 11 of *Calibration*: Change On the two *Calibration* plots, to: On the *Calibration* plot,
GADOTERIDOL INJECTION	*Bacterial endotoxins <85>*	*USP36–NF31*	3701	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2: Change gadoteridol. to: Gadoteridol Injection.
OCTINOXATE	*Assay*	*USP36–NF31*	4556	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Chromatographic system*: Change a 0.32-mm × 25-m column that contains coating G1, to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a 0.32-mm × 25-m column with 0.25-µm thickness of phase G1 coating,
ISOTRETINOIN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 4*	*First Supplement to USP36–NF31*	6000	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 13 of *System suitability*: Add section heads before "Calculate the percentage....": *Analysis Samples*: *Standard solution* and *Sample solution*
CYCLOBENZAPRINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP36–NF31*	6585	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of USP Cyclobenzaprine Related Compound A RS: Change 5-[3-(Dimethylamino)propyl]-10 ,11-dihydro-5*H*-dibenzo[*a*,*d*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-cyclohepten-5-ol. to: 5-[3-(Dimethylam ino) propyl]- 5*H* -diben zo[*a*,*d*]-cyclohepten-5-ol.
TRAMADOL HYDROCHLORIDE	ASSAY/ *Procedure*	*Second Supplement to USP36–NF31*	6715	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *System suitability solution*: Change USP Tramadol Hydrochloride Related Compound A RS to: USP Tramadol Related Compound A RS
BOSWELLIA SERRATA EXTRACT	COMPOSITION /*Content of Keto-Derivatives of ?-Boswellic*	*USP36–NF31*	1367	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Tailing factor*: Change 11-keto-?-boswellic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Acids/System suitability/Suitability requirements							peak to: 3-acetyl-11-keto-?-boswellic acid peak
CARVEDILOL	IMPURITIES/*Organic Impurities, Procedure 3: Carvedilol Related Compound F*	*USP36–NF31*	2822	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Sample solution*: Change Use about 1.9 mL of *Diluent* per mg of the Carvedilol, and sonicate briefly to facilitate dissolution. to: Initially add *Diluent* to fill about 80% of the total volume. Sonicate briefly to facilitate dissolution. Cool, and dilute with *Diluent* to volume.
LEVALBUTEROL INHALATION	ADDITIONAL REQUIREMENTS/*USP*	*USP36–NF31*	4080	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 35: Delete USP Levalbuterol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUTION	*Reference Standards <11>*							Related Compound H RS 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. $C_{14}H_{23}NO_3$ 253.34
RISPERIDONE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5067	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a 98.9/0.5/0.3/0.3 (area %) mixture of the following four compounds: Risperidone (98.9%) Risperidone *cis*-*N*-oxide (0.5%): *cis*-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, *N*-oxide monohydrate. $C_{23}H_{29}FN_4O_4$ 444.50 Bicyclorisperidone (0.3%): 3-(4-fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-2-aza-1-azoniabicyclo[2.2.2]oct-2-ene iodide. $C_{23}H_{28}FIN_4O_4$ 538.40 *Z*-oxime (0.3%): (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								droxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. $C_{23}H_{28}F_2N_4O_2$ 430.29 to: Contains a mixture of four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyrimidin-4-one-*N*-oxide. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z*-*Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VALERIAN TINCTURE	STRENGTH/*Content of Valerenic Acids*	*Second Supplement to USP36–NF31*	6352	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change 90.0%–120.0% to: NLT 0.015% of valerenic acids, calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid.
PARICALCITOL INJECTION	IMPURITIES/*Organic Impurities*/*Chromatographic system*/*Columns*	*Second Supplement to USP36–NF31*	6678	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Guard*: Change 4.6-mm × 7.5-cm to: 4.6-mm × 7.5-mm
FERRIC AMMONIUM CITRATE	*Mercury*	*USP36–NF31*	2469	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 5 of *Standard solutions*: Change 2.5, 5.0, 10.0, and 35.0 µg to: 2.5, 5.0, 10.0,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GRANISETRON HYDROCHLORIDE INJECTION	*Assay*	*USP36–NF31*	3772	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	and 35.0 ng Line 10 of *Procedure*: Change 100(312.41 / 348.87)(*C*/*L*)(r_U / r_S) to: 100(312.41 / 348.87) (*C*/C_U)(r_U / r_S) AND Line of 14 of *Procedure*: Change *L* is as defined above; to: C_U is the nominal concentration, in mg per mL, of granisetron in the *Assay preparation*;
ETHYL OLEATE	SPECIFIC TESTS/ *Viscosity—Capillary Viscometer Methods <911> and Rotational*	*USP36–NF31*	2006	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Change: and to: or

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Rheometer Methods <912>							
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION	*Identification*	*USP36–NF31*	4652	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the *Id entification* test under *Oxymetazoline Hydrochloride Nasal Solution*. to: Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, in a 60-mL separator, and add water to make about 10 mL. Add 2 mL of sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								carbonate solution (1 in 10), extract with 10 mL of chloroform, and transfer the chloroform extract to a second 60-mL separator. Extract the chloroform solution with 10 mL of 0.1 N hydrochloric acid, allow to separate, and discard the chloroform layer. Transfer 8 mL of the acidic aqueous layer to a test tube, neutralize by the dropwise addition of 1 N sodium hydroxide, add 1 drop of 1 N sodium hydroxide in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								excess, and mix. Add a few drops of sodium nitroferricyanide TS and 2 drops of sodium hydroxide solution (15 in 100), mix, and allow to stand for 10 minutes. Add 0.1 N hydrochloric acid dropwise until the pH is between 8 and 9, and allow to stand for 10 minutes. A violet color develops.
LINOLEOYL POLYOXYLGLYCERIDES	IM PURITIES/*Limit of Free Glycerol*	*USP36–NF31*	2068	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration AND Line 10 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change (V_S ? V_B) to: (V_B ? V_S) AND Line 11 of *Analysis*: Change V_S = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume consumed by the *Blank* (mL) to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL)
RIVASTIGMINE TARTRATE	CHEMICAL INFORMATION	*USP36–NF31*	5073	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change 398.41 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POLYSORBATE 80	SPECIFIC TESTS/ *Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*	*USP36–NF31*	2163	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	400.42 Line 1: Change and to: or
BACLOFEN	ASSAY/ *Procedure/ Chromatographic system*	*First Supplement to USP36–NF31*	5951	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Column*: Change 250-cm to: 25.0-cm
SORBITAN MONOSTEARATE	IDENTIFICATION/*A.*	*USP36–NF31*	2214	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the residue obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								criteria: Change 200–215 to: 200–215 on 1-g sample
FILGRASTIM	ASSAY/*Potency*	*Second Supplement to USP36–NF31*	6606	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 7 of *Preparation of cells for analysis*: Change Column 1 is filled with 50 L of *Medium B*. to: Column 1 is filled with 50 µL of *Medium B*.
BUTABARBITAL SODIUM TABLETS	*Identification, Infrared Absorption <197K>*	*USP36–NF31*	2716	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 5 of *Test specimen*: Change Proceed as directed for *Column Partition Chromatography* under *Chromatography <621>*, packing the chromatographic tube as follows.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Pack a chromatographic tube as follows.
DILUTED ALCOHOL	ADDITIONAL REQUIREMENTS	*USP36–NF31*	1874	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Delete *USP Reference Standards <11>* section
DROSPIRENONE	IMPURITIES/*Organic Impurities/Procedure 2*	*USP36–NF31*	3349	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	In footnote b of *Table 4*: Change 5?,17?-Dihydroxy-6?,7?:15?,16?-dimethylene-17?-pregnan-21-carboxylic acid, ?-lactone. to: 5?,17-Dihydroxy-6?,7?:15?,16?-dimethylene-3-oxo-17?-pregnan-21-carboxylic acid, ?-lactone.
CETYL ALCOHOL	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP36–NF31*	1956	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 9 of *Analysis*: Change Result = [(V_S ? V_B) × F]/W to: Result = [(V_B ? V_S) × N × M_r]/W AND Line 10 of *Analysis*: Change V_S = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume consumed by the *Blank* (mL) F = factor, 56.1 to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample* (mL) *N* = actual normality of 1 N sodium hydroxide (mEq/mL) M_r = molecular weight of potassium hydroxide, 56.11
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2/System suitability*	*USP36–NF31*	4327	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Capacity factor*: Change NMT 2 to: NLT 2
HYDROXYETHYL CELLULOSE	SPECIFIC TESTS/ *Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*	*USP36–NF31*	2038	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change and to: or
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND	*Assay for rifampin, isoniazid, and pyrazinamide*	*USP36–NF31*	5047	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 12 of *Procedure*: Change the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ETHAMBUTOL HYDROCHLORIDE TABLETS								*preparation* and the *Assay preparation*, respectively. to: the *Assay preparation* and the *Standard preparation*, respectively.
POLYOXYL 10 OLEYL ETHER	SPECIFIC TESTS/*Average Polymer Length*	*USP36–NF31*	2150	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 9 of *Analysis*: Change Result = [(31 A_2/A_1 ? 3)]/4 to: Result = [(31 × A_2/A_1) ? 3]/4
COMPOUND UNDECYLENIC ACID OINTMENT	*Assay for zinc undecylenate*	*USP36–NF31*	5516	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 15 of *Procedure*: Change 431.94 is the molecular weight of zinc undecylenate; to: M_r is the molecular weight of zinc undecylenate, 431.94;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 16 of *Procedure*: Change 65.39 is the atomic weight of zinc; to: A_r is the atomic weight of zinc, 65.39; AND Line 19 of *Procedure*: Change C_H and C_L are the concentrations, in µg per mL, to: C_{s1} and C_{s2} are the concentrations, in µg per mL,
SORBITAN MONOOLEATE	IDENTIFICATION/*A.*	*USP36–NF31*	2213	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the residue obtained in the *Assay for Fatty*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acids to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance criteria*: Change 192–204 to: 192–204 on 1-g sample
QUININE SULFATE TABLETS	ASSAY/*Procedure*	*First Supplement to USP36–NF31*	6046	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 4 of *Analysis*: Change dihydroquinone sulfate to: dihydroquinine sulfate
STEAROYL POLYOXYLGLYCERIDES	IMPURITIES/*Limit of Free Glycerol*	*USP36–NF31*	2250	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change (V_S ? V_B) to: (V_B ? V_S) AND Line 12 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change V_S = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume consumed by the *Blank* (mL) to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL)
ELEMENTAL I MPURITIES—LITESTING MITS	ANALYTICAL	*USP36–NF31*	151	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change If, by validated processes and supply-chain control, to: If, by process monitoring and supply-chain control,
CARISOPROD	*USP Reference*	*USP36–NF31*	2813	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS	*standards <11>*						*Supplement to USP37–NF32*	Codeine *N* -Oxide RS: Change $C_{18}H_{21}O_4$ to: $C_{18}H_{21}NO_4$
CAPRYLOCAPROYL POLYOXYLGLYCERIDES	IMPURITIES/*Limit of Free Glycerol*	*USP36–NF31*	1922	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration AND Line 10 of *Analysis*: Change (V_T ? V_B) to: (V_B ? V_S) AND Line 11 of *Analysis*: Change V_T = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								consumed by the *Blank* (mL) to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL)
FERUMOXSIL ORAL SUSPENSION	*Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*	*USP36–NF31*	3572	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change and to: or
FERROSOFERRIC OXIDE	IMPURITIES	*USP36–NF31*	2018	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample solution C* in *Limit of Lead (Pb)*: Change *Sample solution* to: *Sample stock solution* AND Line 1 of *Sample solution D* in *Limit of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Lead (Pb): Change *Sample solution* to: *Sample stock solution* AND Line 1 of *Sample solution A* in *Limit of Mercury (Hg) and Nickel (Ni)*: Change *Sample solution* to: *Sample stock solution* AND Line 1 of *Sample solution B* in *Limit of Mercury (Hg) and Nickel (Ni)*: Change *Sample solution* to: *Sample stock solution* AND Line 1 of *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C in *Limit of Mercury (Hg) and Nickel (Ni)*: Change *Sample solution* to: *Sample stock solution*
POLYVINYL ALCOHOL	SPECIFIC TESTS/ *Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913>*	*USP36–NF31*	4830	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change and to: or
OLEOYL POLYOXYLGLYCERIDES	IMPURITIES/*Limit of Free Glycerol*	*USP36–NF31*	2112	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration AND Line 10 of *Analysis*: Change (*V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_S$? V_B) to: (V_B ? V_S) AND Line 11 of *Analysis*: Change V_S = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume consumed by the *Blank* (mL) to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL)
SALICYLIC ACID	*USP Reference standards <11>*	*USP36–NF31*	5098	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of USP Salicylic Acid Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change [CAS-99-96-7]. to: [99-96-7]. AND Line 3 of USP Salicylic Acid Related Compound B RS: Change $C_8H_6O_4$ to: $C_8H_6O_5$

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- …
- Next page Next ›
- Last page Last »